Refine by
Hospital Network Articles & Analysis
51 news found
It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has expanded its relationship with SOPHiA GENETICS to advance its cancer research. ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, today announced the next step in the partnership between the Company and Genomenon, a leading genomic intelligence company, to support better, data-driven outcomes in the rare disease and oncology fields. The two companies have expanded the integration of Genomenon’s Mastermind® Genomic ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from ...
.; Oncohelix in Canada; Dasa in Brazil; Universitätsklinikum Heidelberg in Germany; Stavanger University Hospital in Norway; IUCT Oncopole in France; Synnovis and South West Genomic Laboratory Hub, operating out of North Bristol NHS Trust in the U.K.; Sofiva Genomics in Taiwan; Syndicate Bio in Nigeria; A.O.U. ...
The decentralized SOPHiA DDM™ Platform breaks barriers inherent to the traditional lab approach, allowing for global reach into major hospitals and academic centers. This technology will expedite the implementation of clinical diagnostics and streamline market entry for pharmaceutical companies. ...
It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma ...
This data also provides tremendous value back to hospital partners and clinicians as Caresyntax provides data science reporting and analysis back to hospitals for their value analysis, product evaluation, and value-based care initiatives. ...
Sheba is recognized as one of the world’s leading smart hospitals. Its ARC Innovation Center based in Tel Aviv, Israel will leverage the Caresyntax data-driven surgical intelligence platform to drive foundational improvements across clinical, operational, and financial measures. ...
(TSX-V: PINK)(OTC: PYNKF) (FSE: 4PC) announced another commercial placement of its flagship Perimeter S-Series OCT system at a second hospital within one of the largest healthcare networks in North Texas, which is part of a major national healthcare system. ...
“Our contract with Vizient enables increased access through negotiated pricing to OSSIOfiber technology for thousands of U.S. hospitals and surgery centers,” said OSSIO Chief Commercial and Operating Officer Brennan Marilla. ...
(TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) announced the commercial placement of its flagship Perimeter S-Series OCT system at a hospital that is part of a major national healthcare system and one of the largest healthcare networks in North Texas. ...
We look forward to sharing more site contact information with patients and their clinicians in the future as we activate more sites and some of the largest oncology networks in the US and Europe, making Flamingo-01 available to as many patients as ...
(Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following: As previously disclosed, clinical trial contracts and budgets have been executed at multiple hospitals and the ...
Establishment of new precision molecular oncology research center to drive development of novel targeted cancer therapies for patients with unmet medical need Strategic investment of $140M USD to expand presence in leading center of biotech innovation at Kendall Square in Cambridge Fostering close collaboration with scientists, enhancing global network of academic, ...
ByBayer AG
Negotiations of clinical trial contracts and budgets for the first 3 large hospital sites and the largest oncology network in the US are completed and in the execution phase, paving the way for site initiation visits and subsequent site activation. ...
In 2021, the ActivSight imaging module was cleared by the FDA and successfully used in its first-in-human studies. To date, multiple major hospital networks across the U.S. and Europe have been established as pilot sites. ...
Aidoc’s AI platform is currently used by hospitals, health networks and radiology groups worldwide across multiple service lines. ...
ByAidoc
At least 25 sites are currently in the study start-up process at a variety of university-based hospitals and cooperative networks. Industry leaders for the Phase III clinical trial’s Data Safety Monitoring Board have been recruited and the Steering Committee members are being confirmed. ...
“We’re proud to partner with a leading, innovative hospital network like Novant Health, which serves a large portion of the population in the three states its facilities are located in. ...
ByAidoc